

(12) United States Patent

Hazen et al.

US 8,349,581 B2 (10) **Patent No.:**

(45) **Date of Patent:**

*Jan. 8, 2013

(54) ASSESSING THE RISK OF A MAJOR ADVERSE CARDIAC EVENT IN PATIENTS WITH CHEST PAIN

(75) Inventors: Stanley L. Hazen, Pepper Pike, OH

(US); Marc S. Penn, Beachwood, OH (US); Renliang Zhang, Beachwood, OH

Assignee: The Cleveland Clinic Foundation,

Cleveland, OH (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 552 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 12/265,081

Filed: (22)Nov. 5, 2008

(65)**Prior Publication Data**

US 2009/0061472 A1 Mar. 5, 2009

Related U.S. Application Data

- Continuation of application No. 10/972,058, filed on Oct. 22, 2004, now Pat. No. 7,459,286.
- Provisional application No. 60/513,490, filed on Oct. (60)22, 2003.
- (51) Int. Cl. C12Q 1/28 (2006.01)G01N 33/48 (2006.01)
- (58) Field of Classification Search None See application file for complete search history.

(56)**References Cited**

U.S. PATENT DOCUMENTS

5,122,534	Α	6/1992	Loose et al.
5,731,208	Α	3/1998	Heinecke
5,747,274	Α	5/1998	Jackowski
5,871,946	Α	2/1999	Lucas et al.
5,889,042	A	3/1999	MacLean et al.
5,985,272	A	11/1999	Deby et al.
6,096,556	A	8/2000	Heinecke
6,133,039	A	10/2000	Heinecke
6,268,220	В1	7/2001	Heinecke
6,953,666	В1	10/2005	Kinkade, Jr. et al.
7,223,552	B2	5/2007	Hazen et al.
7,459,286	В1	12/2008	Hazen et al.
2002/0156007	A1	10/2002	Graverson et al.
2002/0164662	A1	11/2002	Hazen et al.
2003/0008373	A1	1/2003	Bertel et al.
2005,0115752	A1	6/2003	Roca
2003/0180218	A1	9/2003	Hazen
200 1 002 00 1	A9	2/2004	Dasseux et al.
2006/0051872	A1	3/2006	Sailor et al.

FOREIGN PATENT DOCUMENTS

EP	389381	9/1990
EP	418486	3/1991
WO	96/04311	2/1996

WO	02/48715	6/2002
WO	02/50550	6/2002
WO	02/066207	8/2002
	OTHED DIT	DI ICATI

OTHER PUBLICATIONS

"Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders" by Heinecke, et al., J Lab Clin Med 1999; 133:321-5.

"The oxidative modification hypothesis of atherogenesis: an overview" by Chisolm, et al., Free Radical Biology & Medicine, vol. 28, No. 12, pp. 1815-1826, 2000.

"Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis" by Carr, et al., FEBS Letters 487 (2000) 176-180

"Comparison of Troponin T Versus Creatine Kinase-MB in Suspected Acute Coronary Syndromes" by McErlean, et al., Am J Cardiol 2000;85:421-426.

"Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide" by Sabatine, et al., Circulation 2002;105:1760-1763.

"Cardiac-Specific Troponin I Levels to Predict the Risk of Martality in Patients with Acute Coronary Syndromes" by Antman, N. Engl J Med 1996;335:1342-9.

"Ability of Troponins to Predict Adverse Outcomes in Patients with Renal Insufficiency and Suspected Acute Coronary Syndromes: A Case-Matched Study" by Van Lente, et al., J Am Coll Cardiol 1999:33:471-8.

Abstract—"Elevated Levels of Plasma Myeloperoxidase, an Oxidative Enzyme Degranulated from Activated Phagocytes, in Patients with Coronary Artery Disease and Acute Coronary Syndromes" by Sugiyama, et al., Supplement to Circulation, vol. 106, No. 19, Nov. 5, 2002, Abstracts from Scientific Sessions, McCormick Place, Chicago, Illinois, Nov. 17-20, 2002.

"Extensive Nitration of Protein Tyrosines in Human Atherosclerosis Detected by Immunohistochemistry" by Beckmann, et al., Biol. Chem. Hoppe-Seyler, vol. 375, pp. 81-88, Feb. 1994.

"Widespread Coronary Inflammation in Unstable Angina" by Buffon, et al., N Engl J Med 2002; 347:5-12.

"Thrombosis and Acute Coronary-Artery Lesions in Sudden Cardiac Ischemic Death" by Davies, et al., N. Engl. J Med 1984; 310:1137-

"Increased Neutrophil Elastase Release in Unstable Angina Pectoris and Acute Myocardial Infarction" by Dinerman, et al., J Am Coll Cardiol 1990; 15:1559-63.

(Continued)

Primary Examiner — Rebecca Prouty Assistant Examiner — Paul Martin

(74) Attorney, Agent, or Firm — Tarolli, Sundheim, Covell & Tummino LLP

(57)ABSTRACT

Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product.

8 Claims, 2 Drawing Sheets